echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The sales of new dosage forms of expectorants under a Shandong pharmaceutical company exceed 4 billion

    The sales of new dosage forms of expectorants under a Shandong pharmaceutical company exceed 4 billion

    • Last Update: 2021-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network News, August 4, August 2, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Yuxin's ambroxol hydrochloride spray was approved for production, and it was the first domestically marketed ambroxol hydrochloride spray product.

    .
    Ambroxol is a commonly used expectorant.
    According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
    .
     
    Ambroxol hydrochloride was developed by Boehringer Ingelheim.
    It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
    It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
    .
     
    According to data from Menet.
    com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
    22% of the total sales.
    Market share
    .
     
      Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms
    .
    Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
    It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
    .
    The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
    .
     
      As a very classic and commonly used expectorant in clinical practice, ambroxol hydrochloride has come to many pharmaceutical companies to develop new dosage forms for it
    .
    Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
    The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
    .
     
      In addition, ambroxol hydrochloride oral regular-release dosage forms and injections have been included in the third and fourth batches of centralized procurement, respectively.
    The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
    .
     
      Selection of National Centralized Procurement of Ambroxol
      Source: Shanghai Sunshine Pharmaceutical Purchasing Network
      Pharmaceutical Network News, August 4, August 2, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Yuxin's ambroxol hydrochloride spray was approved for production, and it was the first domestically marketed ambroxol hydrochloride spray product.

    .
    Ambroxol is a commonly used expectorant.
    According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
    .
     
      Ambroxol hydrochloride was developed by Boehringer Ingelheim.
    It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
    It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
    .
     
      According to data from Menet.
    com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
    22% of the total sales.
    Market share
    .
     
      Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms
    .
    Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
    It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
    .
    The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
    .
     
      As a very classic and commonly used expectorant in clinical practice, ambroxol hydrochloride has come to many pharmaceutical companies to develop new dosage forms for it
    .
    Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
    The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
    .
     
      In addition, ambroxol hydrochloride oral regular-release dosage forms and injections have been included in the third and fourth batches of centralized procurement, respectively.
    The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
    .
     
      Selection of National Centralized Procurement of Ambroxol
      Source: Shanghai Sunshine Pharmaceutical Purchasing Network
      Pharmaceutical Network News, August 4, August 2, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Yuxin's ambroxol hydrochloride spray was approved for production, and it was the first domestically marketed ambroxol hydrochloride spray product.

    .
    Ambroxol is a commonly used expectorant.
    According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
    .
     
      Ambroxol hydrochloride was developed by Boehringer Ingelheim.
    It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
    It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
    .
     
      According to data from Menet.
    com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
    22% of the total sales.
    Market share
    .
    Hospital hospital hospital
     
      Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms
    .
    Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
    It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
    .
    The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
    .
    Child, child, kid
     
      As a very classic and commonly used expectorant in clinical practice, ambroxol hydrochloride has come to many pharmaceutical companies to develop new dosage forms for it
    .
    Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
    The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
    .
    Toddler, toddler, toddler
     
      In addition, ambroxol hydrochloride oral regular-release dosage forms and injections have been included in the third and fourth batches of centralized procurement, respectively.
    The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
    .
     
      Selection of National Centralized Procurement of Ambroxol
      
      Source: Shanghai Sunshine Pharmaceutical Purchasing Network
    Pharmaceutical Purchasing medicine medicine procurement procurement
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.